Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (41-50 of 151) with videos related to

Pageof 16
Sort By:
BJU International|June 26, 2013
Bone metastases in germ cell tumours: lessons learnt from a large retrospective studyMariam Jamal-Hanjani, Anna Karpathakis, Amy Kwan, et al.
Advances in Therapy|November 27, 2013
Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancerZafar Malik, Heather Payne, Jawaher Ansari, et al.
Trials|April 21, 2020
ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancerBen Fulton, Robert Jones, Thomas Powles, et al.
JAMA Network Open|June 15, 2021
Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical TrialAntonio Finelli, Tomasz M Beer, Simon Chowdhury, et al.
European Urology|August 29, 2017
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in EuropeJohann S de Bono, Simon Chowdhury, Susan Feyerabend, et al.
European Urology|August 8, 2016
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical TrialAxel Heidenreich, Simon Chowdhury, Laurence Klotz, et al.
BJU International|November 29, 2014
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approachWaleed Badreldin, Jonathan Krell, Simon Chowdhury, et al.
Urologia Internationalis|October 27, 2010
The effect of sunitinib on immune subsets in metastatic clear cell renal cancerThomas Powles, Simon Chowdhury, Mark Bower, et al.
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
BJU International|June 7, 2014
Is there an antiandrogen withdrawal syndrome with enzalutamide?Alejo Rodriguez-Vida, Diletta Bianchini, Mieke Van Hemelrijck, et al.
Pageof 16

Showing results (41-50 of 151) with videos related to

Sort By:
Pageof 16
BJU International|June 26, 2013
Bone metastases in germ cell tumours: lessons learnt from a large retrospective studyMariam Jamal-Hanjani, Anna Karpathakis, Amy Kwan, et al.
Advances in Therapy|November 27, 2013
Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancerZafar Malik, Heather Payne, Jawaher Ansari, et al.
Trials|April 21, 2020
ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancerBen Fulton, Robert Jones, Thomas Powles, et al.
JAMA Network Open|June 15, 2021
Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical TrialAntonio Finelli, Tomasz M Beer, Simon Chowdhury, et al.
European Urology|August 29, 2017
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in EuropeJohann S de Bono, Simon Chowdhury, Susan Feyerabend, et al.
European Urology|August 8, 2016
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical TrialAxel Heidenreich, Simon Chowdhury, Laurence Klotz, et al.
BJU International|November 29, 2014
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approachWaleed Badreldin, Jonathan Krell, Simon Chowdhury, et al.
Urologia Internationalis|October 27, 2010
The effect of sunitinib on immune subsets in metastatic clear cell renal cancerThomas Powles, Simon Chowdhury, Mark Bower, et al.
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
BJU International|June 7, 2014
Is there an antiandrogen withdrawal syndrome with enzalutamide?Alejo Rodriguez-Vida, Diletta Bianchini, Mieke Van Hemelrijck, et al.
Pageof 16